Journal of the American Academy of Dermatology · 2011
Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: a population-based case-control study.
Сравнительное исследованиеСтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Torti Dorothea C, Christensen Brock C, Storm Craig A, Fortuny Joan, Perry Ann E, Zens Michael S, Stukel Therese, Spencer Steven K, Nelson Heather H, Karagas Margaret R
Аннотация
BACKGROUND: Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are potentially chemopreventive.
OBJECTIVE: We examined the relation between NSAID use and nonmelanoma skin cancer in a population-based case-control study.
METHODS: NSAID and analgesic use was analyzed in 1484 participants: 535 with squamous cell carcinoma (SCC), 487 with basal cell carcinoma (BCC), and 462 control subjects.
RESULTS: Use of NSAIDs, particularly aspirin, was associated with a reduced odds ratio (OR) of SCC, especially tumors positive for p53 (OR 0.29; 95% confidence interval 0.11-0.79) or with PTCH loss of heterozygosity (OR 0.35; 95% confidence interval 0.13-0.96). Although not considered a NSAID, decreased ORs of both basal cell carcinoma and SCC were observed in relation to use of paracetamol (acetaminophen). Risk of BCC was unrelated to NSAID use.
LIMITATIONS: Self-reported drug use was a limitation.
CONCLUSIONS: This study supports the hypothesis that NSAIDs, aspirin in particular, may reduce risk of SCC and may affect specific molecular subtypes of SCC.
OBJECTIVE: We examined the relation between NSAID use and nonmelanoma skin cancer in a population-based case-control study.
METHODS: NSAID and analgesic use was analyzed in 1484 participants: 535 with squamous cell carcinoma (SCC), 487 with basal cell carcinoma (BCC), and 462 control subjects.
RESULTS: Use of NSAIDs, particularly aspirin, was associated with a reduced odds ratio (OR) of SCC, especially tumors positive for p53 (OR 0.29; 95% confidence interval 0.11-0.79) or with PTCH loss of heterozygosity (OR 0.35; 95% confidence interval 0.13-0.96). Although not considered a NSAID, decreased ORs of both basal cell carcinoma and SCC were observed in relation to use of paracetamol (acetaminophen). Risk of BCC was unrelated to NSAID use.
LIMITATIONS: Self-reported drug use was a limitation.
CONCLUSIONS: This study supports the hypothesis that NSAIDs, aspirin in particular, may reduce risk of SCC and may affect specific molecular subtypes of SCC.
Предметные рубрики MeSH
AcetaminophenAdultAge DistributionAgedAnalgesicsAnti-Inflammatory Agents, Non-SteroidalAspirinBasal Cell CarcinomaCarcinoma, Squamous CellCase-Control StudiesCohort StudiesConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedOdds RatioReference ValuesSex DistributionSkin Neoplasms